Sorrento Therapeutics, Inc.
Case Number:
4:23-bk-90085
Court:
Nature of Suit:
Firms
- Husch Blackwell
- Martin P. Eramo APC
- Gray Reed
- Chapman & Cutler
- Andrews Myers
- Christian Levine Law Group
- Finch Thornton
- Coats Rose
- Pashman Stein
- Norton Rose
- McGuireWoods
- Maynard Nexsen
- Buchalter APC
- Warshaw Burstein
- Rusty Hardin & Associates
- K&L Gates
- Quinn Emanuel
- Locke Lord
- Pillsbury Winthrop
- ASK LLP
- Cowles & Thompson
- Harvest LLP
- Gibbs Giden
- Munsch Hardt
- Sheppard Mullin
- Kean Miller
- Tran Singh
- Franklin Soto Leeds
- Probus Law Firm
- Kane Russell
- Baker Botts
- Thompson Coburn
- Doyle Restrepo
- WilmerHale
- Porter Hedges
- Troutman Pepper
- Davis Graham
- Duane Morris
- Tucker Arensberg
- Sidley Austin
- Ohashi & Horn
- Ferguson Braswell
- DLA Piper
- Katten Muchin
- Miller Nash LLP
- Clark Hill
- Reed Smith
- Glenn Agre
- Ross Smith & Binford
- Greenberg Traurig
- Paul Hastings
- Shook Hardy
- Jones Walker
- Bressler Amery
- Jones Day
- Jackson Walker LLP
- Latham & Watkins
- Milbank LLP
Companies
- The Scripps Research Institute
- Cetera Financial Institutions
- HSBC Holdings PLC
- PCI Pharma Services
- The Charles Schwab Corp.
- Sorrento Therapeutics Inc.
- Interactive Brokers Group Inc.
- BMO Harris Bank NA
- Barclays PLC
- Apex Clearing Corporation
- Bank of America Corp.
- FMR LLC
- Moelis & Co.
- Raymond James Financial Inc.
- Mayo Foundation for Medical Education and Research
- Edward D. Jones & Co. LP
- Wedbush Securities Inc.
- The Goldman Sachs Group Inc.
- Phillip Capital Inc.
- TR Capital Management LLC
- Precision for Medicine Holdings Inc.
- Protiviti Inc.
- NantWorks LLC
- FTI Consulting Inc.
- JPMorgan Chase & Co.
- ABN AMRO Bank NV
- Stretto Inc.
- Fortis Advisors LLC
- BMO Capital Markets Corp.
- Oracle Corp.
- Emas Pharma Ltd.
- LPL Financial Holdings Inc.
- Pershing Group LLC
- New England Biolabs Inc.
- Robert Half Inc.
- Prospect Medical Holdings Inc.
- Charles River Laboratories International Inc.
- The Bank of New York Mellon Corp.
- Morgan Stanley
- Kilroy Realty Corporation
- UBS Group AG
Sectors & Industries:
-
January 24, 2024
Latham Ducks Sanctions In Sorrento Ch. 11
A Texas bankruptcy judge Wednesday declined to level sanctions against Latham & Watkins LLP over their disclosures about their work with a lawyer who was dating the judge overseeing Sorrento Therapeutics Inc.'s Chapter 11, but did not yet rule on sanctioning Jackson Walker LLP in the same case, saying further inquiry was needed.
-
January 05, 2024
Latham Denies Exploiting Texas Judge Scandal For Fees
Latham & Watkins LLP has fired back against accusations it knowingly exploited an improper relationship between a Texas judge and an attorney to inflate its fees during the bankruptcy of Sorrento Therapeutics Inc., claiming the firm had absolutely no knowledge of the headline-grabbing ethics scandal before the news broke last fall.
-
November 30, 2023
Sorrento Gets OK For 5-Month Ch. 11 Wind-Down
A Texas bankruptcy judge on Thursday approved drug developer Sorrento Therapeutics Inc.'s disclosure statement and its Chapter 11 liquidation plan, which would go into effect in five months, possibly offering the debtor an opportunity to find an alternative to liquidation.
-
November 29, 2023
Sorrento Investors Ask To Probe Counsel Conflicts In Ch. 11
Shareholders of bankrupt drug developer Sorrento Therapeutics Inc. have demanded the company turn over information about the debtor's counsel getting advice from an attorney who was romantically involved with the judge that formerly presided over the case.
-
October 18, 2023
Sorrento Cleared For $20M JV Sale In Ch. 11 Case
Bankrupt drug developer Sorrento Therapeutics Inc. received court approval Wednesday in Texas for a $20 million sale of its stake in a joint venture to its South Korean partner, giving it access to much-needed cash as it pursues a Chapter 11 plan.
-
October 12, 2023
Sorrento Seeks Quick Timeline On Process For Ch. 11 Plan
Sorrento Therapeutics Inc. has asked a Texas bankruptcy judge for a speedy hearing on its disclosure statement for its Chapter 11 plan, saying delay may eat up value creditors can recover.
-
October 11, 2023
Sorrento To Sell JV Stake For $20M In 'Urgent' Bid For Cash
Sorrento Therapeutics Inc. has asked a Texas bankruptcy judge to approve a sale of its stake in a joint venture with pharmaceutical company Yuhan Corp. to the South Korean firm for $20 million, citing an immediate need for liquidity to cover Chapter 11 expenses.
-
September 12, 2023
Sorrento OK'd For Alternative $110M Ch. 11 Stock Sale
Bankrupt drug developer Sorrento Therapeutics received a Texas court's approval Tuesday for subsidiary Scilex Holding Co. to buy its own stock back from its parent for $110 million after the original buyer said closing conditions weren't met for its court-approved acquisition.
-
August 25, 2023
Sorrento Approved For $105M Scilex Stock Sale In Ch. 11
Bankrupt drug developer Sorrento Therapeutics received approval Friday in Texas court for a $105 million sale of its stake in subsidiary Scilex Holding Co. after a bankruptcy judge declined to reopen the auction for those assets as requested by other Scilex shareholders who wished to make a bid.
-
August 07, 2023
Sorrento OK'd For New $100M Ch. 11 DIP Loan In Texas
Bankrupt drug developer Sorrento Therapeutics secured a Texas judge's approval Monday for a $100 million emergency replacement of an expired debtor-in-possession loan from Oramed Pharmaceuticals, after the debtor set aside a proposed $200 million offer for stock in non-debtor affiliate Scilex Holding Co.
- ← Previous
- 1
- 2
- 3
- Next →